Actinium Pharmaceuticals, Inc.
Cash Flow History
| Period | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| Mar 2017 | $-5.4M | $-5.4M | $8.3K | $1.0M |
| Jun 2017 | $-7.1M | $-7.1M | $8.4K | $1.1M |
| Sep 2017 | $-5.9M | $-5.9M | $6.8K | $681.8K |
| Dec 2017 | $-3.2M | $-3.2M | $1.3K | $639.6K |
| Mar 2018 | $-5.5M | $-5.5M | $7.0K | $579.9K |
| Jun 2018 | $-4.2M | $-4.2M | $19.8K | $425.8K |
| Sep 2018 | $-6.6M | $-6.7M | $58.7K | $405.9K |
| Dec 2018 | $-4.3M | $-4.3M | $10.6K | $387.0K |
| Mar 2019 | $-5.5M | $-5.5M | $51.0K | $316.0K |
| Jun 2019 | $-5.4M | $-5.4M | $8.0K | $277.0K |
| Sep 2019 | $-5.6M | $-5.6M | $0 | $391.0K |
| Dec 2019 | $-5.0M | $-5.0M | $5.0K | $311.0K |
| Mar 2020 | $-5.9M | $-5.9M | — | $372.0K |
| Jun 2020 | $-4.5M | $-4.5M | — | $210.0K |
| Sep 2020 | $-5.0M | $-5.0M | — | $288.0K |
| Dec 2020 | $-6.3M | $-6.3M | — | $384.0K |
| Mar 2021 | $-5.6M | $-5.6M | $4.0K | $376.0K |
| Jun 2021 | $-4.6M | $-4.6M | $61.0K | $459.0K |
| Sep 2021 | $-5.6M | $-5.7M | $68.0K | $411.0K |
| Dec 2021 | $-5.1M | $-5.1M | $0 | $448.0K |
| Mar 2022 | $-5.8M | $-5.8M | $7.0K | $421.0K |
| Jun 2022 | $27.9M | $27.6M | $270.0K | $425.0K |
| Sep 2022 | $-5.7M | $-5.8M | $73.0K | $970.0K |
| Dec 2022 | $-7.8M | $-7.8M | $16.0K | $979.0K |
| Mar 2023 | $-15.1M | $-15.2M | $76.0K | $993.0K |
| Jun 2023 | $-13.6M | $-13.7M | $47.0K | $1.0M |
| Sep 2023 | $-11.1M | $-11.2M | $30.0K | $921.0K |
| Dec 2023 | $-7.5M | $-7.5M | $0 | $927.0K |
| Mar 2024 | $-7.4M | $-7.4M | $11.0K | $1.4M |
| Jun 2024 | $-8.0M | $-8.0M | $0 | $1.4M |
| Sep 2024 | $-12.0M | $-12.0M | $0 | $1.3M |
| Dec 2024 | $-5.8M | $-5.8M | $0 | $1.2M |
| Mar 2025 | $-7.6M | $-7.6M | — | $8.9M |
| Jun 2025 | $-5.4M | $-5.4M | — | $197.0K |
| Sep 2025 | $-6.3M | $-6.3M | — | $109.0K |
| Dec 2025 | $-5.3M | $-5.3M | — | $10.0K |
| Mar 2026 | $-5.9M | $-5.9M | $2.0K | $11.0K |
| Jun 2026 | $-5.2M | $-5.7M | $478.0K | $118.0K |